300725.SZ
药石科技
SZSE · Healthcare · M 科研服务 · CN
CNY 48.31
−6.12%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.0B | 2.0B | 1.7B | 1.7B | 1.6B |
| Cost of Revenue | 1.4B | 1.4B | 1.0B | 991.7M | 869.5M |
| Gross Profit | 633.7M | 608.5M | 642.6M | 733.5M | 725.2M |
| Operating Expenses | |||||
| R&D Expense | 117.0M | 108.7M | 107.3M | 169.2M | 168.3M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 179.2M | 175.8M | 181.2M | 200.2M | 207.5M |
| Selling & Marketing Expense | 71.6M | 66.8M | 57.3M | 53.2M | 41.0M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 423.7M | 407.8M | 396.0M | 495.5M | 426.8M |
| Cost and Expenses | 1.8B | 1.8B | 1.4B | 1.5B | 1.3B |
| Operating Income (EBIT) | 225.5M | 210.5M | 251.2M | 184.6M | 296.7M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 222.5M | 207.6M | 248.9M | 221.4M | 323.3M |
| Income Tax Expense | 25.6M | 23.9M | 29.4M | 24.0M | (2.6M) |
| Bottom Line | |||||
| Net Income | 196.8M | 183.7M | 219.5M | 197.4M | 314.2M |
| Earnings from Cont. Ops | 196.8M | 183.7M | 219.5M | 197.4M | 325.9M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 196.8M | 183.7M | 219.5M | 197.4M | 314.2M |
| Per Share | |||||
| Basic EPS | CN¥0.93 | CN¥0.88 | CN¥1.10 | CN¥0.99 | CN¥1.58 |
| Diluted EPS | CN¥0.93 | CN¥0.88 | CN¥1.10 | CN¥0.98 | CN¥1.57 |
| Revenue Per Share | CN¥8.71 | CN¥9.46 | CN¥8.46 | CN¥8.65 | CN¥8.02 |
| Shares | |||||
| Basic Shares Outstanding | 232.8M | 208.8M | 199.6M | 199.4M | 198.9M |
| Diluted Shares Outstanding | 232.8M | 208.8M | 199.6M | 199.4M | 198.9M |
| Profitability Metrics | |||||
| EBITDA | — | 351.8M | 387.9M | 304.4M | 389.4M |
| D&A | — | 141.3M | 136.7M | 119.8M | 92.7M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026